The result at week 68: Continued semaglutide 2.4 mg: lost an additional 7.9% of body weight (total loss from baseline: 17.4%) Switched to placebo: regained 6.9% of body weight (net loss from baseline: 5.0%) Thats a roughly 15-point difference in body weight between the two groups at the end of the trial, attributable entirely to whether the medication continued
Therefore, if you hear someone talking about an injection for weight loss and diabetes, they are referring to GLP-1 receptor agonists like semaglutide or tirzepatide, not insulin
Documentation of metabolic dysfunction (insulin resistance, prediabetes, lipid abnormalities) improves approval odds significantly
This leads to Pink1 accumulation on the OMM, which promotes the recruitment of the E3 ligase Parkin to mitochondria [275, 276]
Here are some key aspects of GLP-1: Insulin Secretion: GLP-1 stimulates the secretion of insulin from the pancreas in response to elevated blood glucose levels
